BioCryst Pharmaceuticals (NASDAQ:BCRX) versus Nordic Nanovector ASA (OTCMKTS:NRNVF) Head to Head Analysis

Nordic Nanovector ASA (OTCMKTS:NRNVF) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Nordic Nanovector ASA and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nordic Nanovector ASA	N/A	N/A	N/A
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Valuation & Earnings

This table compares Nordic Nanovector ASA and BioCryst Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nordic Nanovector ASA	N/A	N/A	N/A	N/A	N/A
BioCryst Pharmaceuticals	$940.61 million	2.67	$263.86 million	($1.50)	-6.55

BioCryst Pharmaceuticals has higher revenue and earnings than Nordic Nanovector ASA.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Nordic Nanovector ASA and BioCryst Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nordic Nanovector ASA	0	0	0	0	0.00
BioCryst Pharmaceuticals	0	4	8	0	2.67

BioCryst Pharmaceuticals has a consensus target price of $20.60, indicating a potential upside of 109.78%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Nordic Nanovector ASA.

Summary

BioCryst Pharmaceuticals beats Nordic Nanovector ASA on 7 of the 9 factors compared between the two stocks.

About Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.